Skip to main content
Loading Loading
 
  • Sign In
  • Donate
  • Home
  • Create Account
  • Cart
 Facebook icon LinkedIn icon Twitter icon
Sign In

Archived Public Policy Statements


2009

  • American College of Clinical Pharmacology® Position Statement on Direct-to-Consumer/Patient Advertising of Genetic Testing

2007

  • American College of Clinical Pharmacology® Position Statement on the Use of Microdosing in the Drug Development Process

2005

  • ACCP Letter of Comment on 2005 Best Pharmaceuticals for Children Act (BPCA) (04/28/2005)

2003

  • A Rational Look At Progress vs. The Precautionary Principle
  • Epidemiology In Decision-Making How Epidemiology Can Be Properly Used in Decision-Making - Its Strengths and Limitations
  • How Can I Judge Good Science?
  • The Annapolis Accords for Cost-Benefit Analysis Principles to Judge a Cost-Benefit Analysis
  • The Annapolis Accords for Risk Assessment A Citizen's Guide For Risk Assessment and Risk Management, A Set Of Principles To Guide a Risk Analysis
  • The Use of Toxicology in Risk Assessment and Decision-Making - Its Strengths and Limitations

2002

  • A special supplement released by The Journal of Clinical Pharmacology on the clinical consequences of Marijuana use (10/21/2002)

2000

  • ACCP Response to Institute of Medicine Report, "To Err is Human: Building a Safer Health System"

1999

  • "Clinical Pharmacology: A Retrospective View of the Future"

Connect With Us

 Facebook icon LinkedIn icon Twitter icon 

Contact Us

Info@ACCP1.org

(Postal) PO Box 1758 Ashburn, VA  20146-1758       (Shipping)  21750 Red Rum Drive, Ste 137, Ashburn, VA 20147      (571) 291-3493

© American College of Clinical Pharmacology®                                                                                                                                                       Privacy Policy
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##